Patent 9463197 was granted and assigned to National Taiwan Normal University on October, 2016 by the United States Patent and Trademark Office.
A method for treating an abnormal polyglutamine-mediated disease is disclosed, which comprises: administering a pharmaceutical composition comprising a trehalose-based compound to a subject in need. Additionally, the pharmaceutical composition optionally further comprises a trehalase inhibitor.